Multiple myeloma screening

Multiple myeloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple Myeloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiograph and Ultrasound

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Multiple myeloma screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple myeloma screening

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple myeloma screening

CDC on Multiple myeloma screening

Multiple myeloma screening in the news

Blogs on Multiple myeloma screening

Directions to Hospitals Treating Multiple myeloma

Risk calculators and risk factors for Multiple myeloma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]; Shyam Patel [3]

## Overview

[edit | edit source]

There is insufficient evidence to recommend routine screening for multiple myeloma in the general population. However, laboratory assessment should be done often (typically once per year or more frequently) for patients who have monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

## Screening

[edit | edit source]

### Monoclonal gammopathy of undetermined significance

[edit | edit source]

Monoclonal gammopathy of undetermined significance (MGUS) carries a 1% annual risk (on average) for progression to active multiple myeloma and therefore requires monitoring. Given the risk of progression, patients should be screened via monitoring of complete blood count (CBC), serum protein electrophoresis (SPEP), and free light chain ratio typically once yearly. The frequency of screening may vary depending on the MGUS risk group. High-risk patients may need more frequent monitoring because high-risk MGUS carries a higher risk for progression to multiple myeloma. High-risk MGUS is defined by the presence of M-spike > 1.5g/dl, non-IgG subtype of the paraprotein, and abnormal free light chain ratio.[1]

### Smoldering multiple myeloma

[edit | edit source]

Smoldering multiple myeloma carries a 10% annual risk (on average) for progression to active multiple myeloma and therefore requires monitoring. Given the risk of progression, patients should be screened via monitoring of complete blood count (CBC), serum protein electrophoresis (SPEP), and free light chain ratio typically once yearly or more frequently. The frequency of screening may vary depending on the smoldering multiple myeloma risk group. High-risk smoldering multiple myeloma patients may need more frequent monitoring since this carries a higher risk for progression to active multiple myeloma.

### Multiple myeloma

[edit | edit source]

There is insufficient evidence to recommend routine screening for active multiple myeloma in the general population, but patients with MGUS or smoldering multiple myeloma should have routine laboratory checks to monitor for progression to active multiple myeloma.[2][3]

## References

[edit | edit source]

1. ↑ Kyle RA, Rajkumar SV (2011). "Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)". Oncology (Williston Park). 25 (7): 578–86. PMC 3923465. PMID 21888255.
2. ↑ Multiple Myeloma Prevention and Screening.(2015)http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/multiple-myeloma/prevention/index.html
3. ↑ Can multiple myeloma be prevented?(2015)http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-prevention